Overview
Current Appointments & Affiliations
Professor of Medicine
·
2021 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
1988 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.
Journal Article Adv Ther · September 2025 INTRODUCTION: Pegcetacoplan, the first C3 and C3b inhibitor for paroxysmal nocturnal hemoglobinuria (PNH), demonstrated efficacy and safety in C5 inhibitor-experienced and -naive patients in the phase 3 studies PEGASUS (NCT03500549) and PRINCE (NCT04085601 ... Full text Link to item CiteOral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.
Journal Article Lancet Haematol · June 2025 BACKGROUND: The factor B inhibitor iptacopan improved 24-week outcomes in adult patients with paroxysmal nocturnal haemoglobinuria in the phase 3 APPLY-PNH and APPOINT-PNH trials; the trial extension periods assessed clinical activity and safety up to 48 w ... Full text Link to item CitePatient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies.
Journal Article Blood Adv · April 22, 2025 Iptacopan, a first-in-class, oral, selective complement factor B inhibitor, demonstrated efficacy and safety as monotherapy in C5 inhibitor (C5i)-experienced (APPLY-PNH; NCT04558918) and C5i-naive (APPOINT-PNH; NCT04820530) patients with paroxysmal nocturn ... Full text Link to item CiteRecent Grants
External Quality Assurance Program Oversight Laboratory (EQAPOL)
ResearchInvestigator · Awarded by National Institute of Allergy and Infectious Diseases · 2024 - 2031CLNP023C12303
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2023 - 2025Novartis: Single-Arm, Open-Label, Ph2 of MBG453 added to Hypomethylating Agent for MDS
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2022 - 2025View All Grants
Education
University of Texas, Dallas ·
1985
M.D.